Niacinamide

Alternative Medicine Review

Volumn 7, Issue 6, 2002, Pages 525-529

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

NICOTINAMIDE; ANTICONVULSIVE AGENT;

ADENOSINE DIPHOSPHATE RIBOSYLATION; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTHRITIS; DIABETES MELLITUS; DIARRHEA; DOSE RESPONSE; DRUG ACTIVITY; DRUG MECHANISM; DRUG STRUCTURE; FLATULENCE; HEADACHE; HEARTBURN; HUMAN; NAUSEA; NUTRIENT; PELLAGRA; RADIOSENSITIVITY; SCHIZOPHRENIA; SHORT SURVEY; SKIN DISEASE; STRUCTURE ANALYSIS; VERTIGO; VOMITING; ACUTE DISEASE; ANIMAL; ARTICLE; CHEMISTRY; DRUG INTERACTION; INSULIN DEPENDENT DIABETES MELLITUS; KNEE OSTEOARTHRITIS;

ACUTE DISEASE; ANIMALS; ANTICONVULSANTS; DIABETES MELLITUS, TYPE 1; DRUG INTERACTIONS; HUMANS; NIACINAMIDE; OSTEOARTHRITIS, KNEE; SCHIZOPHRENIA; SKIN DISEASES;

EID: 0036885802     PISSN: 10895159     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (44)

1. Warburg O, Christian W. Co-ferment problem. Biochemie 1934;274:122-125.
2. McCreanor GM, Bender DA. The metabolism of high intakes of tryptophan, nicotinamide, and nicotinic acid in the rat. Br J Nutr 1986;56:577-586.
3. th Ed. New York, NY: McGraw Hill; 1995:1555-1571.
4. Stratford MR, Dennis MF, Hoskin P, et al. Nicotinamide pharmacokinetics in humans: Effect of gastric acid inhibition, comparison of rectal vs oral administration and the use of saliva for drug monitoring. Br J Cancer 1996;74:16-21.
5. Petley A, Macklin B, Renwick AG, Wilkin TJ. The pharmacokinetics of nicotinamide in humans and rodents. Diabetes 1995;44:152-155.
6. Knip M, Douek IF, Moore WP, et al. Safety of high dose nicotinamide: A review. Diabetologia 2000;43:1337-1345.
7. Sandler S, Andersson A. Long-term effects of exposure of pancreatic islets to nicotinamide in vitro on DNA synthesis, metabolism and B-cell function. Diabetologia 1986;29:199-202.
8. Yonemura Y, Takashima T, Miwa K, et al. Amelioration of diabetes mellitus in partially depancreatized rats by poly(ADP-ribose) synthetase inhibitors. Evidence of islet B-cell regeneration. Diabetes 1984;33:401-404.
9. Elliott RB, Pilcher CC, Stewart A, et al. The use of nicotinamide in the prevention of type 1 diabetes. Ann N Y Acad Sci 1993;696:333-341.
10. Burkart V, Koike T, Brenner HH, Kolb H. Oxygen radicals generated by the enzyme xanthine oxidase lyse rat pancreatic islet cells in vitro. Diabetologia 1992;35:1028-1034.
11. Kallmann B, Burkhart V, Kroncke KD, et al. Toxicity of chemically generated nitric oxide towards pancreatic islet cells can be prevented by nicotinamide. Life Sci 1992;51:671-678.
12. Radons J, Heller B, Burkle A, et al. Nitric oxide toxicity in islet cells involves poly(ADP-ribose) polymerase activation and concomitant NAD+ depletion. Biochem Biophys Res Commun 1994;199:1270-1277.
13. Mohler H, Polc P, Cumin R, et al. Nicotinamide is a brain constituent with benzodiazepine-like actions. Nature 1979;278:563-565.
14. Miesel R, Kurpisz M, Kroger H. Modulation of inflammatory arthritis by inhibition of poly(ADP ribose) polymerase. Inflammation 1995;19:379-387.
15. McCarty MF, Russell AL. Niacinamide therapy for osteoarthritis - Does it inhibit nitric oxide synthase induction by interleukin 1 in chondrocytes? Med Hypotheses 1999;53:350-360.
16. Marks JB, Skyler JS. Clinical review 17: Immunotherapy of type 1 diabetes mellitus. J Clin Endocrinol Metab 1991;72:3-9.
17. Pozzilli P, Visalli N, Signore A, et al. Double blind trial of nicotinamide in recent-onset IDDM (the IMDIAB III study). Diabetologia 1995;38:848-852.
18. Chase HP, Butler-Simon N, Garg S, et al. A trial of nicotinamide in newly diagnosed patients with type 1 (insulin dependent) diabetes mellitus. Diabetolgia 1990;33:444-446.
19. Lewis CM, Canafax DM, Sprafka JM, Barbosa JJ. Double-blind randomized trial of nicotinamide on early-onset diabetes. Diabetes Care 1992;15:121-123.
20. Amiel SA, Caprio S, Sherwin RS, et al. Insulin resistance of puberty: A defect restricted to peripheral glucose metabolism. J Clin Endocrinol Metab 1991;72:277-282.
21. Elliott RB, Pilcher CC, Fergusson DM, Stewart AW. A population based strategy to prevent insulin-dependent diabetes using nicotinamide. J Pediatr Endocrinol Metab 1996;9:501-509.
22. Cunningham JJ. Micronutrients as nutriceutical interventions in diabetes mellitus. J Am Coll Nutr 1998;17:7-10.
23. Lampeter EF, Klinghammer A, Scherbaum WA, et al. The Deutsche Nicotinamide Intervention Study: An attempt to prevent type 1 diabetes. DENIS Group. Diabetes 1998;47:980-984.
24. Hoffer A. Safety, side effects and relative lack of toxicity of nicotinic acid and nicotinamide. Schizophrenia 1969;1:78-87.
25. Hoffer A. The vitamin paradigm wars. Townsend Letters for Doctors and Patients 1996;June:56-60.
26. Green RG. Subclinical pellagra: Its diagnosis and treatment. Schizophrenia 1970;2:70-79.
27. Osmund H, Hoffer A. Massive niacin treatment in schizophrenia: Review of a nine-year study. Lancet 1962;I:316-320.
28. Wittenborn JR. Niacin in the long-term treatment of schizophrenia. Arch Gen Psychiatry 1973;28:308-315.
29. Kaufman W. The Common Form of Joint Dysfunction: Its Incidence and Treatment. Brattleboro, VT: EL Hildreth and Company, 1949.
30. Kaufman W. The use of vitamin therapy to reverse certain concomitants of aging. J Am Geriatr Soc 1955;3:927-936.
31. Jonas WB, Rapoza CP, Blair WF. The effect of niacinamide on osteoarthritis: A pilot study. Inflamm Res 1996;45:330-334.
32. Loo WJ, Dean D, Wojnarowska F. A severe persistent case of recurrent pemphigoid gestationis successfully treated with minocycline and nicotinamide. Clin Exp Dermatol 2001;26:726-727.
33. Khanna N, Pandhi RK, Gupta S, Singh MK. Response of chronic bullous dermatosis of childhood to a combination of dapsone and nicotinamide. J Eur Acad Dermatol Venereol 2001;15:368.
34. Khumalo NP, Murrell DF, Wojnarowska F, Kirtschig G. A systematic review of treatments for bullous pemphigoid. Arch Dermatol 2002;138:385-389.
35. Chaidemenos GC. Tetracycline and niacinamide in the treatment of blistering skin diseases. Clin Dermatol 2001;19:781-785.
36. Hakozaki T, Minwalla L, Zhuang J, et al. The effect of niacinamide on reducing cutaneous pigmentation and suppression of melanosome transfer. Br J Dermatol 2002;147:20-31.
37. Lei TC, Virador VM, Vieira WD, Hearing VJ. A melanocyte-keratinocyte coculture model to assess regulators of pigmentation in vitro. Anal Biochem 2002;305:260-268.
38. Agote M, Viaggi M, Kreimann E, et al. Influence of nicotinamide on the radiosensitivity of normal and goitrous thyroid in the rat. Thyroid 2001;11:1003-1007.
39. Denekamp J, Fowler JF. ARCON - Current status: Summary of a workshop on preclinical and clinical studies. Acta Oncol 1997;36:517-525.
40. Kryzhanovskii GN, Shandra AA. Effect of diazepam, carbamazepine, sodium valproate and their combinations with vitamin preparations on epileptic activity. Biull Eksp Biol Med 1985;100:545-547. [Article in Russian]
41. Bourgeois BF, Dodson WE, Ferrendelli JA. Interactions between primidone, carbamazepine, and nicotinamide. Neurology 1982;32:1122-1126.
42. Winter SL, Boyer JL. Hepatic toxicity from large doses of vitamin B3 (nicotinamide). N Engl J Med 1973;289:1180-1182.
43. Anonymous. Vitamin B complex, niacin. In: McEvoy GK, ed. American Hospital Formulary Service Drug Information. Bethesda, MD: American Society of Hospital Pharmacists; 1995:1685-1687.
44. Elliott RB, Chase HP. Prevention or delay of type 1 (insulin-dependent) diabetes mellitus in children using nicotinamide. Diabetologia 1991;34:362-365.